Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:3382
Name liposarcoma
Definition A connective tissue cancer that arises in fat cells in deep soft tissue retroperitoneum and the extremities.
Source DiseaseOntology.org
Alt Ids DOID:3939
Path disease disease of cellular proliferation cancer organ system cancer musculoskeletal system cancer connective tissue cancer liposarcoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
MDM2 amp TP53 wild-type SAR405838 liposarcoma sensitive detail...
TP53 wild-type MK-8242 liposarcoma predicted - sensitive detail...
TP53 wild-type ALRN-6924 liposarcoma predicted - sensitive detail...
MDM2 amp GDC-0575 + Gemcitabine liposarcoma predicted - sensitive detail...
MDM2 amp unspecified MDM2 inhibitor liposarcoma predicted - sensitive detail...
TP53 wild-type KRT-232 liposarcoma predicted - sensitive detail...
MDM2 amp BI 907828 liposarcoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00356031 Phase II Bevacizumab Bevacizumab and Radiation Therapy for Sarcomas Completed USA 0
NCT01506596 Phase II Pazopanib Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma Completed USA 0
NCT02048371 Phase II Regorafenib A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas Completed USA 0
NCT02210104 Phase I Ipilimumab Cyclophosphamide Adoptive Therapy Using Antigen-Specific CD4 T-Cells Withdrawn 0
NCT02275286 Phase Ib/II Trabectedin Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients (TRASTS) Recruiting ITA | FRA | ESP 0
NCT02301039 Phase II Pembrolizumab A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas Completed USA 0
NCT02343172 Phase Ib/II Ribociclib + Siremadlin Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma Completed FRA | ESP | DEU | CAN 2
NCT02357810 Phase II Pazopanib + Topotecan Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas Completed USA 0
NCT02606461 Phase II Selinexor KCP-330-020 SEAL (Selinexor in Advanced Liposarcoma) (SEAL) Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL 2
NCT02846987 Phase II Abemaciclib Study of Abemaciclib in Dedifferentiated Liposarcoma Active, not recruiting USA 0
NCT02923778 Phase II Talimogene laherparepvec Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery Active, not recruiting USA | CAN 0
NCT02978859 Phase II Sitravatinib MGCD516 in Advanced Liposarcoma and Other Soft Tissue Sarcomas Active, not recruiting USA 0
NCT03009201 Phase I Doxorubicin + Ribociclib Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery Completed USA 0
NCT03074318 Phase Ib/II Avelumab + Trabectedin Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery Terminated USA 0
NCT03114527 Phase II Everolimus + Ribociclib Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) Active, not recruiting USA 0
NCT03190174 Phase Ib/II Nab-rapamycin + Nivolumab Nivolumab (Opdivo) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma Completed USA 0
NCT03307616 Phase II Ipilimumab + Nivolumab Nivolumab Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma Active, not recruiting USA 0
NCT03422679 Phase Ib/II CB-103 Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies Terminated USA | FRA | ESP | DEU 2
NCT03474094 Phase II Atezolizumab Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy (RT-Immune) Recruiting GBR | FRA 0
NCT03548428 Phase II Atezolizumab Stereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc) (Stereosarc) Recruiting FRA 0
NCT03719430 Phase II Doxorubicin + Olaratumab + Sotigalimab APX005M, Doxorubicin, Olaratumab in Advanced Sarcoma Active, not recruiting USA 0
NCT03860207 Phase Ib/II Hu3F8-BsAb Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers Terminated USA 0
NCT03880123 Phase I Ixazomib + Selinexor Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma Withdrawn USA 0
NCT03899805 Phase II Eribulin + Pembrolizumab A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas Active, not recruiting USA 0
NCT03964233 Phase I BI 907828 + Ezabenlimab + Miptenalimab BI 907828 + Ezabenlimab A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 in Combination With BI 754091 (Ezabenlimab) Recruiting USA | GBR | FRA | ESP | DEU | BEL | AUS 4
NCT04076579 Phase II Olaparib + Trabectedin Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma Active, not recruiting USA 0
NCT04205227 Phase Ib/II ENB003 + Pembrolizumab ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors Active, not recruiting USA | AUS 0
NCT04216953 Phase Ib/II Atezolizumab + Cobimetinib MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma (COTESARC) Recruiting FRA 0
NCT04242238 Phase I Avelumab + Vimseltinib Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas Active, not recruiting USA 0
NCT04420975 Phase I BO-112 + Nivolumab Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma Active, not recruiting USA 0
NCT04557449 Phase I Letrozole + PF-07220060 Fulvestrant + PF-07220060 PF-07220060 Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4i) Recruiting USA | GBR 6
NCT04906876 Phase II Docetaxel + Elraglusib + Gemcitabine 9-ING-41Combined With Chemotherapy in Adolescents and Adults Withdrawn USA 0
NCT05116800 Phase II Docetaxel + Elraglusib + Gemcitabine Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma Withdrawn USA 0
NCT05389462 Phase I ADCT-601 + Gemcitabine ADCT-601 A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors Recruiting USA | GBR | FRA | ESP 0
NCT05836571 Phase II Ipilimumab + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma Recruiting USA | CAN 0
NCT05841563 Phase I PM54 Clinical Trial of PM54 in Advanced Solid Tumors Patients. Recruiting USA | ESP | BEL 0
NCT06025747 Phase I Abemaciclib Evaluation of Abemaciclib and Radiation Therapy Before Surgery for the Treatment of High-Risk Adipocytic Retroperitoneal Sarcoma Not yet recruiting USA 0